Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Pharvaris N.V. (PHVS)

32.82 +0.87 (+2.72%)
At close: October 28 at 4:00:00 PM EDT
32.82 0.00 (0.00%)
After hours: October 28 at 4:01:07 PM EDT
Trade PHVS on Coinbase
Chart Range Bar
Loading chart for PHVS
  • Previous Close 31.95
  • Open 31.79
  • Bid 23.19 x 200
  • Ask 41.13 x 200
  • Day's Range 31.74 - 32.86
  • 52 Week Range 21.02 - 43.25
  • Volume 381,039
  • Avg. Volume 774,847
  • Market Cap (intraday) 2.304B
  • Beta (5Y Monthly) -2.46
  • PE Ratio (TTM) --
  • EPS (TTM) -3.06
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 57.42
  • Zacks Rating Neutral

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

pharvaris.com

148

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PHVS
18.27%
S&P 500 (^GSPC)
13.13%

1-Year Return

PHVS
44.90%
S&P 500 (^GSPC)
12.38%

3-Year Return

PHVS
85.21%
S&P 500 (^GSPC)
88.08%

5-Year Return

PHVS
82.33%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -47.84M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q2

FY26

-40M
-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

40.84
57.42 Average
32.82 Current
78.69 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/23/2026
Analyst B of A Securities
Rating Action Upgrade
Rating Buy
Price Action Maintains
Price Target 44 -> 44

Statistics

View More

Valuation Measures

Annual
As of 10/26/2026
  • Market Cap

    2.21B

  • Enterprise Value

    1.85B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    6.45

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.32%

  • Return on Equity (ttm)

    -70.46%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -170.92M

  • Diluted EPS (ttm)

    -3.06

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    318.28M

  • Total Debt/Equity (mrq)

    0.22%

  • Levered Free Cash Flow (ttm)

    -90.36M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

32.82 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: